Abstract
Transfer RNA-derived small RNAs (tsRNAs) are conventional non-coding RNAs (ncRNAs) with a length between18 and 40 nucleotides (nt) playing a crucial role in treating various human diseases including tumours. Nowadays, with the use of high-throughput sequencing technologies, it has been proven that certain tsRNAs are dysregulated in multiple tumour tissues as well as in the blood serum of cancer patients. Meanwhile, data retrieved from the literature show that tsRNAs are correlated with the regulation of the hallmarks of cancer, modification of tumour microenvironment, and modulation of drug resistance. On the other side, the emerging role of tsRNAs as biomarkers for cancer diagnosis and prognosis is promising. In this review, we focus on the specific characteristics and biological functions of tsRNAs with a focus on their impact on various tumours and discuss the possibility of tsRNAs as novel potential biomarkers for cancer diagnosis and prognosis.
Introduction
Non-coding RNAs (ncRNAs) that exist widely in cells are not translated into proteins and can be roughly divided into two categories: small ncRNAs (sncRNAs) and long ncRNAs (lncRNAs) (1). Recent sequencing data reveal that ncRNA transcripts are four times than protein-coding RNA transcripts in human cells (2, 3). However, the majority of ncRNAs and their functions in mammals are underappreciated (4). LncRNAs are longer than 200 nt and include the most nuclear ncRNAs (5). SncRNAs are up to 200 nt in length and mainly include small interfering RNAs (siRNAs), microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs), and small nucleolar RNAs (snoRNAs) (6ā8). These sncRNAs have been extensively studied in the past two decades and exert complex roles in biological processes, such as inhibition of translation, metabolic modulation and others (9ā11). In this review, we will focus on an emerging functional sncRNA called transfer RNA-derived small RNAs (tsRNAs).
Transfer RNAs (tRNAs) are a group of classic sncRNAs, which transport amino acids to messenger RNAs (mRNAs) during the process of translation (12). The typical two-dimensional configuration of mature tRNAs has a stem-loop structure. As it has been reported in previous studies, from the 5ā to 3ā end the stem-loop constructions compose the acceptor stem, the D-loop, the anti-codon loop, the variable loop and the TĻC loop (13). Recent data have unveiled the role of tRNAsā posttranscriptional modifications to dysregulation of certain genes resulting in the development of different human diseases (14, 15).
As a novel group of sncRNAs derived from tRNAs, transfer RNA-derived small RNAs (tsRNAs) are produced by specific nucleases (16). They cut specific sites of the precursor or mature tRNAs, when found under stress, infection, tumorigenesis, and other specific conditions, which are barely connected with parental tRNA abundance (17ā20). Recently, multiple tsRNAs have been discovered in various tumour cells (21). Meanwhile, emerging evidence has suggested that tsRNAs play a critical role in regulating cancer hallmarks, modifying tumour microenvironment, and modulating drug resistance by involving multiple biological processes, such as inhibition of mRNA translation, promotion of ribosome biogenesis, and regulation of epigenetic processes (22ā26). Moreover, these findings highlight that tsRNAs can potentially be considered as biomarkers for cancer diagnosis and prognosis (27ā29).
Herein, we provide a comprehensive summary of the tsRNAsā characteristics. Furthermore, we discuss the dysregulations and functions of tsRNAs in numerous cancers and explore the possibility of tsRNAs as diagnostic and prognostic biomarkers for cancers.
Biogenesis and Characteristics of tsRNAs
tsRNAs are conventional sncRNAs that can be classified into two major subtypes: tRNA-related small RNA fragments (tRFs) with a length of 18-30 nt and tRNA halves with a length of 30-40 nt (FigureĀ 1A). tsRNAs were initially classified as degradation debris of tRNAs during biological processes and were closely related to parental tRNA abundance. However, accumulating evidence indicates that tsRNAs are enzyme-digested products of exact nucleases that cut into concrete sites of precursor or mature tRNAs under specific conditions, such as stress, infection, neurodegeneration, and tumorigenesis (30ā33). In addition, authors report that tsRNAs have various types of RNA modifications, including methylation modification, modification of the 5ā-hydroxyl terminal and 2ā, 3ā-cyclic phosphorylation modification (34). These modifications have been proposed to depend on their precursor tRNAs and the type of enzymatic processing (35). Thus tsRNAs are not considered random tRNA degradation byproducts, but a cluster of functional molecules with high stability and inherent conservation (35, 36). Interestingly, data reveal the pivotal role of all these types of regulatory tsRNAs in post-transcriptional regulation in cancer cells (37, 38).
FigureĀ 1
Five classes of tRFs are known and they are tRF-1s, tRF-2s, tRF-3s, tRF-5s, and i-tRFs (39). Besides the fact that the tRF-1s are products of the ribonuclease Z (RNase Z) clipping off the 3ā-end of precursor tRNAs (40), other tRFs have proven to be enzyme-digested products of mature tRNAs (41). Dicer, angiogenin (ANG), and other particular ribonucleases participate in the digesting processes of these mature tRNAs (FigureĀ 1B). A tRF-5s is generated from the 5ā-tail of a mature tRNA to the D-loop (tRF-5a) or the sequence between the D-loop and the anti-codon loop (tRF-5b and tRF-5c) of a mature tRNA. tRF-5s are typically produced by Dicer and ANG cleavage into the different termination site between 5ā end and the anti-codon loop. tRF-3s that mainly contain tRF-3a and tRF-3b are derived from the TĻC loop to the 3ā end of mature tRNAs. Dicer is the main ribonuclease cutting into the TĻC loop to produce tRF-3s. In that sense, tRF-2s comprise the sequence straddling the anti-codon loop of mature tRNAs with variable lengths. Alternatively, i-tRFs comprise the anti-codon loop of mature tRNAs and sections of the D-loop and T-loop. The specific mechanism of tRF-2s/i-tRFs production remains unclear (42).
tRNA halves, as the name suggests, are derived from the 5ā² end of mature tRNAs to the terminus of the anti-codon loop (5ā²-tRNA halves) or start at the anti-codon loop and proceed to the 3ā end of mature tRNAs (3ā²-tRNA halves). Findings retrieved from the literature indicate that these tsRNAs are mainly involved in hypoxic conditions, nutritional deficiency, heat shock, and other conditions of stress (43). Therefore, tRNA halves are universally called tRNA-derived stress-induced RNAs (tiRNAs) that act as effectors of cellular stress responses (44). tiRNAs are known to be produced by ANG which knockdown considerably reduces the level of tiRNAs in human U2OS cells (45). In a recent study, Su etĀ al. found that production of certain tiRNAs was dependent on RNase L cleavage and hence ANG was not the only ribonuclease to produce tiRNAs (46). Interestingly, the other type of tRNA halves known as the sex hormone-dependent tRNA-derived RNAs (SHOT-RNAs) are not induced by various stress stimuli, but they are highly expressed in hormone receptor-positive breast and prostate cancer cells (47). Therefore, SHOT-RNAs represent a separated category of tRNA halves with distinct specificity of expression (48).
tsRNA biogenesis is regulated by tRNA modifications. It has been reported that two (cytosine-5) RNA methyltransferases, DNMT2 and NSUN2, add 5-methylcytosine (m5C) modification to particular tRNAs. Thus they protect tRNAs from cleavage into tsRNAs in mice (49). The tRNA methyltransferase 10 homolog A (TRMT10A) was also found to mediate N1-methylguanine (m1G) modification to several tRNAs and decrease tsRNAās production (50). In addition, the queuine tRNA-ribosylthansferase catalytic subunit 1 (QTRT1)-dependent addition of queuosine (Q) modification to several tRNAs increases tRNA stability in HEK293T cells (51). Moreover, 2ā-O-methylation modification of the C34 residue in the tRNAMet can inhibit tRNA degradation by ANG and decrease tsRNA production (52). Except for preventing tsRNA biogenesis, some tRNA modifications have promoted tRNA cleavage into tsRNAs (35). For example, pseudouridylate synthase 7 homolog (PUS7)-dependent addition of pseudouridine (ĪØ) modification to several tRNAs promotes tsRNA biogenesis in stem cells (53). A recent study demonstrated that the knockout of ALKBH1 or ALKBH3 genes increases N1-methyladenine (m1A) modification in several tRNAs and lowers the abundance of tsRNAs in human 293T cells (54). In another study, the 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) modification at position 34 (wobble position) was found to promote efficient cleavage of substrate tRNAs into yeast tsRNAs (55). In this regard, it is of great importance to mention that tRNA modification not only correlates to tsRNA biogenesis but is also associated with changes in tsRNA functions. The last occurs due to the abovementioned modifications, which have posed challenges for tsRNA library preparation and the conduction of studies concerning the mechanism of tsRNAs.
To date, the next-generation sequencing data allowed a deeper analysis of the obtained evidence, researchers have made remarkable progress in terms of the biogenesis and classification of tsRNAs. Meanwhile, online databases like tsRBase and OncotRF providing validated tsRNAs are emerging (56, 57) (TableĀ 1). The last is a result of the fact that important biological processes have been demonstrated to be strongly correlated with tsRNAs, which has drawn broad attention, especially in cancer studies.
TableĀ 1
| Database | Description | URL link |
|---|---|---|
| tRFdb | A relational database of tRFs | http://genome.bioch.virginia.edu/trfdb/ |
| MINTbase | A database for interaction of mitochondrial and tRFs | http://cm.jefferson.edu/MINTbase/ |
| tRFexplorer | A database shows tRFs expression profile in each TCGA tumor type | https://trfexplorer.cloud/ |
| tRF2Cancer | A database identifies tRFs from sequencing datasets in various cancers | http://rna.sysu.edu.cn/tRFfinder/ |
| OncotRF | A database provides the comprehensive tRF information related to various cancers | http://bioinformatics.zju.edu.cn/OncotRF |
| tsRBase | A comprehensive database for tsRNA expression and function | http://www.tsrbase.org/search.php |
tsRNA databases.
Biological Processes Correlated With tsRNAs
The biological processes correlated with tsRNAs involve multiple pathways such as inhibition of mRNA translation, promotion of ribosome biogenesis, and regulation of epigenetic processes (17). FigureĀ 2 comprehensively summarizes the three main tsRNA-associated molecular mechanisms (FigureĀ 2).
FigureĀ 2
Inhibition of mRNA Translation
tsRNAs are thought to inhibit mRNA translation by either regulating mRNA stability or interfering with translation initiation and elongation (19). Unlike other sncRNAs, tsRNAs regulate mRNA stability by either canonical miRNA pathway, binding to Argonaute 2 (Ago2) protein or non-canonical miRNA pathway, incorporating into other Argonaute (Ago) family proteins (58, 59).Ā For example, CU1276 was considered as a type of tRFs in human germinal centre B cells and was a DICER1-mediated cleavage production of tRNA-Gly. This specific tRFs repressed replication protein A1 (RPA1) protein by complementarily targeting the 3āUTR of its mRNA, thus suppressing proliferation. More specifically, CU1276 incorporated into silencing complexes with each of the four Argonautes via analysis of coprecipitated RNA using an Ago-reactive antibody in human kidney 293 cells (60). A study conducted on colorectal cancer cells showcased that a tRF derived from tRNALeu functions as miRNAs and inhibits the Notch pathway by interacting with the 3āUTR of Notch ligand jagged 2 (JAG2) mRNA, and suppresses cancer stem-like cells in colorectal cancer progress (61). Li etĀ al. found that some ANG-dependent tRF-3s cleaved the target mRNA by guiding the Ago2 protein, which was similar to the miRNA induced silencing complex (62). Concerning the miRNA-like gene silencing pathway, Haussecker etĀ al.Ā found that some tRFs regulated mRNA stability via binding to Ago proteins except for the Ago2 protein forming in this way tRF-induced silencing complexes (63). Subsequent reports indicated that these tRF-induced silencing complexes probably targeted the coding regions, 3āUTRs and 5āUTRs of mature mRNAs (64ā66). Furthermore, tRFs mainly derived from tRNA-Glu, tRNA-Asp, tRNA-Gly, and tRNA-Tyr were demonstrated to competitively bind to Y-box-binding protein 1 (YBX1), which enabled the displacement of multiple oncogenic transcripts from the YBX1 protein in breast cancer cells. Subsequently, this led to a reduction in the stability of oncogenic transcripts and inhibited the progress of breast cancer cells (67).
A considerable body of evidence has shown that tsRNAs inhibited translation by interfering with translation initiation and elongation. Specifically, Lyons etĀ al. identified that G-quadruplex (G4) structures containing tiRNAs (G4-tiRNAs) displaced eIF4G, impaired the assembly of 40S ribosomal subunit and ultimately inhibited the translation initiation (68, 69). Moreover, Gebetsberger etĀ al. demonstrated that a tRF-5s derived from tRNA-Val acted as a translation elongation brake for the polysome assembly inĀ Haloferax volcanii, which bound the small ribosomal subunit and repressed the consequent protein biosynthesis (70).
Briefly, the piled-up evidence proposes that some tsRNAs probably weaken protein biosynthesis by inhibiting translation processes. Further efforts are needed to explore the regulatory networks between mRNA targets and tsRNAs.
Promotion of the Ribosome Biogenesis
Recent studies proved that some tsRNAs promoted ribosome biogenesis via the regulation of ribosomal RNAs (rRNAs) and ribosomal proteins (22). An example of the last assertion is the tRF-3s in Protozoa that was shown to recruit the Tetrahymena Piwi 12 (Twi12), exoribonuclease 2 (Xrn2) and Twi-associated novel 1 (Tan1) proteins to compose the pre-rRNA splicing complex Twi12/Xrn2/Tan1 (TXT), which processed the precursor rRNAs to mature rRNAs (71, 72). However, whether tRFs promoted rRNA production in higher-level classified living organisms is still unknown. Additionally, a group of tRF-3s derived from tRNALeu was shown to bind RPS28 or RPS15 mRNAs to promote ribosomal protein translation (22, 73). Yet, the available evidence is insufficient to indicate the extent of the relation of tiRNAs to ribosome biogenesis. In conclusion, the regulatory pathways of tsRNAs role in ribosome biogenesis are the focus for future studies.
Regulation of Epigenetic Processes
tsRNAs have gradually emerged as a novel epigenetic factor. On one hand, tsRNAs act as epigenetic regulators that maintain the genomeās stability by targeting and suppressing transposable elements (23). Studies have shown that some tRF-3s silenced the LTR-retrotransposons by blocking reverse transcription and by post-transcriptional silencing (74, 75). Furthermore, abundant tiRNAs in the mature sperm altered the transcriptome of mouse embryos without changing the DNA methylation status. The observed phenomenon indicated that tiRNAs acted as epigenetic factors in the mature sperm but also affected the next-generation phenotyping (76ā78). On the other hand, tsRNAs regulated the epigenetic processes via targeting DNA methylation and histone modifications (79). Data have revealed that tRF-5s derived from tRNA-GluĀ was combined with Piwi-like protein 4 (PIWIL4) thus recruiting the SET domain bifurcated histone lysine methyltransferase 1 (SETDB1), SUV39H1 histone lysine methyltransferase (SUV39H1), and heterochromatin protein 1β (HP1β) proteins leading to the methylation of the promoter region and inhibition of CD1A expression in monocytes (80, 81). These findings suggest that aĀ new chapter has been unfolded regarding the tsRNA-related epigenetic regulations, but yet there is a shortage of knowledge concerning the precise functions of tsRNAs in the epigenetic control, which eventually will be determined on a case-by-case basis.
The Role of tsRNAs in Cancer Development and Promotion
The functions of tsRNAs have drawn broad attention across the scientific world concerning cancers. So far, numerous studies have demonstrated that tsRNAs have pivotal functions in regulating proliferation, apoptosis, and migration of cancer cells, modifying tumour microenvironment, and modulating cancer drug resistance (29). Moreover, recent clinical research has revealed that tsRNAs were commonly detected in the serum samples from tumour patients (82). Therefore, tsRNAs have great potential to serve as novel biomarkers for various types of cancers, such as breast, lung, colorectal, ovarian and other types (TableĀ 2).
TableĀ 2
| Cancer | tsRNAs | Effect | Mechanism | Clinical Value | References |
|---|---|---|---|---|---|
| Breast cancer | tRFGlu-YTC tRFAsp-GTC tRFGly-TCC | Tumor suppressor | Displace oncogenic transcripts from YBX1 and then suppress cell proliferation | Need to be further studied | (67) |
| tiRNAAsp-GUC tiRNAHis-GUG tiRNALys-CUU | Tumor promoter | Involvement in cell proliferation | Potential biomarker for ER+ patient | (47) | |
| ts-112 | Tumor promoter | Target RUNX1 and promote tumor-related activities | Need to be further studied | (83) | |
| tRFLys-CTT-010 | Tumor promoter | Interact with G6PC and then promote cell proliferation | Need to be further studied | (84) | |
| tRF-Arg-CCT-017, tRF-Gly-CCC001, tiRNA-Phe-GAA-003 | Unknown | Unknown | Diagnostic and prognosis biomarker | (85) | |
| tRF-31-87R8WP9I1EWJ0 | Unknown | Unknown | Diagnostic and prognosis biomarker | (86) | |
| tDRā000620 | Unknown | Unknown | Diagnostic biomarker | (87) | |
| tRF3E | Tumor suppressor | Interact with nucleolin and repress the translation of P 53 | Diagnostic biomarker | (88) | |
| tRF-30-JZOYJE22RR33 ,tRF-27-ZDXPHO53KSN | Unknown | Unknown | Prognostic biomarker | (89) | |
| Gastric cancer | tiRNA-5034-GluTTC-2 | Unknown | Unknown | Diagnostic biomarker | (90) |
| tRF-Glu-TTC-027 | Tumor suppressor | Regulate progression via MAPK pathway | Potential target for clinical therapy | (91) | |
| tRF-19-3L7L73JD | Tumor suppressor | Inhibit proliferation and Promote apoptosis | Diagnostic biomarker | (92) | |
| tRF-33-P4R8YP9LON4VDP | Tumor suppressor | Inhibit proliferation and migration | Diagnostic biomarker | (93) | |
| tRF-24-V29K9UV3IU | Tumor suppressor | Inhibit proliferation and migration by regulating the Wnt pathway | Potential target for clinical therapy | (94) | |
| Colorectal cancer | tRF-24-NMEH623K25, tRF-30- XSXMSL73VL4Y, tRF-29- QU7BPN6ISBJO, tRF-27- Q99P9P9NH5N | Tumor promoter | Ā Regulate the progression of colon cancer via cGMP-PKG signaling pathway | Diagnostic biomarker | (95) |
| tRF/miR-1280 | Tumor suppressor | Suppress stem cell-like cells and metastasis | Potential diagnostic marker | (61) | |
| tiRNAHis-GTG | Tumor promoter | Regulate LATS2 and promote progression | Need to be further studied | (26) | |
| 50-tiRNA-Val, 50-tiRNA-Cys, 50-tiRNA-Ala | Tumor promoter | Promote migration and invasion | Potential target for diagnosis | (96) | |
| tRF-20-M0NK5Y93 | Tumor suppressor | Inhibit metastasis by targeting Claudin-1 | Need to be further studied | (97) | |
| Prostate cancer | tRF-1001 | Tumor promoter | ELAC2 dependent production and promote proliferation | Need to be further studied | (40) |
| tiRNAAsp-GUC tiRNAHis-GUG tiRNALys-CUU | Tumor promoter | Involvement in cell proliferation | Potential diagnostic marker | (47) | |
| tRF-544 tRF-315 | Tumor promoter | Target GADD45A and protect cancer cells from apoptosis | Prognostic biomarker for recurrence | (98, 99) | |
| Lung cancer | tRFLeu-CAG | Tumor promoter | Regulate AURKA and increase proliferative ability of cancer | Potential diagnostic marker | (100) |
| ts-46 ts-47 | Tumor suppressor | Interfere with S1P pathway and inhibit cancer progress | Need to be further studied | (17) | |
| ts-3676 ts-4521 | Tumor suppressor | Interact with PIWI proteins and inhibit cancer progression | Need to be further studied | (101) | |
| Hepatocellular cancer | tRNA-ValTAC-3, tRNA-GlyTCC-5, tRNA-ValAAC-5, tRNA-GluCTC-5 | Unknown | Unknown | Diagnostic biomarker | (102) |
| tRFGly | Tumor promoter | Promote cell migration by targeting NDFIP2 | Potential therapeutic target | (103) | |
| Ovarian cancer | tRF-03357 | Tumor promoter | Promote proliferation by targeting HMBOX1 | Potential diagnostic marker | (104) |
| tRF-03358 | Unknown | Unknown | Diagnostic biomarker | (105) | |
| Pancreatic cancer | tRF-3-Leu-AAG-1-1, tRF-3-Gln-CTG-1-1, tRF-3-AlaCGC-1-1 | Tumor promoter | Target cancer-related pathways | Diagnostic biomarker | (106) |
| tRF-Pro-CGG | Tumor suppressor | inhibits the metastasis of pancreatic cancer | Diagnostic biomarker | (85) | |
| Leukemia | Ā i-tRF-PheGAA | Unknown | Unknown | Biomarker for prognosis | (107) |
| Ā i-tRF-GlyGCC | Unknown | Unknown | Prognostic biomarker | (108) | |
| Ā i-tRF-GlyCCC | Unknown | Unknown | Diagnostic and prognostic biomarker | (109) | |
| ts-101, ts-53, ts-44 | Tumor suppressor | Target TCL1 and suppress progression | Need to be further studied | (110) | |
| tRF-LeuAAG/TAG | Unknown | Unknown | Prognostic biomarker | (111) | |
| Renal cell carcinoma | tRFVal-AAC tiRNALeu-CAG-5 tiRNAArg-CCT-5 tiRNAGlu-CTC-5 tiRNALys-TTT-5 | Tumor suppressor | Act in a tumor-suppressive manner | Prognostic biomarker | (112, 113) |
| Osteosarcoma | tiRNAAla tiRNACys | Tumor promoter | Trigger assembly of stress granules | Need to be further studied | (114) |
| B cell lymphoma | CU1276/tRF-3018 | Tumor suppressor | Associate with Ago proteins and suppress proliferation | (60) | |
| Bladder cancer | 5ā-tRF-Lys-CTT | Unknown | Unknown | Diagnostic and prognosis biomarker | (115) |
| Papillary thyroid cancer | tRF-39-0VL8K87SIRMM12E2, tRF-38-0VL8K87SIRMM12V tRF-34-YSV4V47Q2WW1J1, tRF27-PIR8YP9LON3 | Unknown | Unknown | Diagnostic biomarker | (116) |
| Oral squamous cell carcinoma | tRF-20-S998LO9 | Unknown | Unknown | Prognosis biomarker | (117) |
Summary of cancer-associated tsRNAs.
Dysregulations of tsRNAs in Cancers
The first abnormally expressed tsRNA (tRF-1001) was found in various cancer cells (40) and since then the number of dysregulated tsRNAs have increased. The role of tsRNA in oncology research was revisited and many entered clinical trials. In that sense, Fabris and colleagues reported a significant downregulation of ts-53 and ts-101 in chronic lymphocytic leukaemia (CLL) (110). Similarly, Maute etĀ al. observed that some tRF-3s were also downregulated in germinal centre-derived lymphomas (60). tDR-7816 was distinctly downregulated in breast cancer cells (118, 119). However, in cancer tissues from non-small cell lung cancer (NSCLC), the tRF-Leu-CAG was significantly upregulated, while the serum level of tRF-Leu-CAG was positively correlated to cancer stages (100). Likewise, Papadimitriou etĀ al. reported a significant elevation of the tRF-Lys-CTT in bladder tumors and a positive association with clinical prognosis (115). Interestingly, data demonstrated diverse expression of three different tRF-5s in the testicular germinoma (120). As a result, data suggested that deregulation of tsRNAs turned to be a key factor in the progress of cancers thus introducing the tsRNAs as cancer biomarkers in the medical practice.
The Role of tsRNAs in the Regulation of Cancer Hallmarks
Cell proliferation, apoptosis, and migration are well-known hallmarks of cancers and determinants of the prognosis of cancer patients. tRF-1001 derived from the pre-tRNASer was the first tsRNA found to promote the proliferation of prostate cancer cells (40). Moreover, Lee etĀ al. found that the knockdown of tRF-1001 impaired cell proliferation and resulted in the accumulation of cells in interphase with phenotypes reversed by transfecting cells with the synthetic tRF-1001 oligoribonucleotide. In another study, SHOT-RNAs were significantly upregulated in hormone receptor-positive prostate and breast carcinoma cells, and the proliferation of cancer cells was distinctly decreased when transfecting cancer cells with SHOT-RNA-targeted siRNAs (47). These observations suggested that SHOT-RNAs probably stimulated cell proliferation in hormone receptor-positive prostate and breast carcinoma cells. Regarding ovarian cancer cells, Zhang etĀ al. found that tRF-03357 was upregulated and that this tsRNA promoted the proliferation of ovarian cancer cells via downregulation of the Homeobox-containing protein 1 (HMBOX1) transcription factor (104). On the other hand, the expression of HMBOX1 in high-grade serous ovarian cancer cells was significantly lower than that in normal ovarian cells. However, the specific pathway involved in tRF-03357 regulating HMBOX1 and other tRFs that modulated the progression of ovarian cancer required further investigation. Contrary to tRF-03357, a tRF-5s derived from tRNA-Glu has been elucidated to target the breast cancer anti-estrogen resistance protein 3 (BCAR3) and hence to inhibit the proliferation of ovarian carcinoma cells (121). Zhou and colleagues demonstrated that the decrease in the expression of BCAR3 and the increase of tRF suppressed the proliferation of ovarian cancer cells.Ā The authors further confirmed that the same tRF bound directly to the 3āUTR of BCAR3 mRNA, which then resulted in downregulation of the BCAR3 protein. Furthermore, previous studies have suggested that tRF-Leu-CAG affected the proliferation of lung carcinoma cells by targeting the Aurora Kinase A (AURKA) protein, which participated in the control of cell cycle and the regulation of the cell division (100, 122). Even more, a recent study showed that tsRNA-5001a was significantly upregulated in lung adenocarcinoma tissues and the overexpression of tsRNA-5001a significantly promoted cell proliferation (123).Ā Hu etĀ al. discovered that tsRNA-5001a promoted cancer cell proliferation by targeting the growth arrest and DNA damage inducible gamma (GADD45G) and downregulating its expression (123). GADD45G is widely known for its antitumor function (124). However, the relationship between tRFs and other DNA repair genes similar to GADD45G in lung adenocarcinoma patients needs to be further explored. In this regard, Maute etĀ al. demonstrated that CU1276, as one of the representatives of tRF-3s, inhibited the proliferation of B cell lymphoma via the RPA1-dependent pathway (60, 125). Additionally, Shen etĀ al. found that levels of tRF-33-P4R8YP9LON4VDP were significantly downregulated in plasma samples of gastric patients and that this tsRNA inhibited the proliferation of gastric carcinoma cells (93).
Cell apoptosis, also known as programmed cell death, is an important hallmark of cancer cells (126). Recently, it has been suggested that tRF-315 targeted the growth arrest and DNA damage inducible alpha (GADD45A) gene known for being a tumour suppressor, which then regulated the cell cycle, and finally protected the prostate cancer cells from apoptosis (99). Furthermore, 5ā-tiRNA-His targeted the large tumour suppressor kinase 2 (LATS2) protein to turn off the downstream signalling pathway and finally upregulated the anti-apoptotic-related genes (26). Alternatively, Elbarbary etĀ al. found that 5ā-half-tRNA(Glu), working as sgRNA, stimulated tRNA 3ā processing endoribonuclease (tRNase Z) to cleave the target protein phosphatase 1F (PPM1F) mRNA and thus affected the apoptosis of human kidney 293 cells via suppressing the expression of the PPM1F protein (127). These data are an indication that various tsRNAs are negatively connected with the apoptosis of cancer cells. On the contrary, in breast carcinoma, 5ā²-tiRNA-Val was shown to alter the colony formation. Another study confirmed that 5ā²-tiRNA-Val targeted the Frizzled-3 (FZD3) protein, attenuating the Wnt/β-catenin pathway, and finally promoting the apoptosis of cancer cells (118).
Cell migration is also the main trait of malignant tumours and indicates the degree of cancer progression (128). Retrieved data from clinical trial research link distant metastasis with significant tRFs dysregulations in uveal melanoma (129). Further, Birch etĀ al. found that these dysregulated tRFs affected the retrotransposon activity and probably played a pivotal role in cancer cell migration (130). Even more, a tRF derived from tRNALeu was determined as an inhibitor of migration by preventing the premetastatic niche (PMN) formation in colorectal cancer cells (131). The endothelialāmesenchymal transition (EMT) is a critical factor for the regulation of the cancer cellsā migration (132). Recently, it has been demonstrated that tRFs derived from tRNA-Gly targeted the EMT-related proteins and regulated the migration of hepatocellular carcinoma (103). Regarding other malignancies, tsRNAs were shown to regulate the migration of cancer cells. Specifically, tRF-3019a was found to promote the migration of gastric cancer cells via targeting tumour suppressors, while tRF-17-79MP9PP inhibited the migration of breast cancer cells via regulating the thrombospondin 1 (THBS1)-mediated transforming growth factor beta 1 (TGF-β1)/SMAD family member 3 (smad3) signalling pathway (133, 134).
The Role of tsRNAs in Modifying the Tumour Microenvironment
The tumour microenvironment (TME) consists of tumour cells, cancer stem cells, as well as of tumour stromal cells including endothelial cells, fibroblasts, and immune cells, in addition to non-cellular components of the extracellular matrix (135). In recent years, it has been demonstrated that tsRNAs orchestrated the tumour processesĀ by modifying the TME (136). On the one hand, accumulating evidence has shown that exosomes produced by tumour cells possess multiple tRFs that modify the TME (137). For example, exosomes in oral squamous cell carcinoma (OSCC) were shown toĀ contain multiple tsRNAs that are involved in transforming TME to conditions favourable for cancer progression (25). However, the mechanism through which this favourable environment for OSCC growth and metastasisĀ is promoted by tsRNAs remains unknown and needs further studies. Interestingly, exosomal tsRNAs derived from tRNA-Val, tRNA-Gly, and tRNA-Glu were shown to participate in the modulation of TME in hepatic carcinoma (137). Regardless of the above-discussed, the specific biological functions of exosome-derived tRFs in tumour regulation remain to be further investigated. On the other hand, recent studies have drawn increasing attention to cancer stem cells (CSCs) as important components of the TME, while they are involved in numerous tumour biological processes (138, 139). Meanwhile, data indicated that some tRFs have modified the TME by regulating the CSC functions (140). Huang and colleagues reported that tRFs derived from tRNALeu were found to suppress CSC functions via the inactivation of Notch signaling in colorectal cancer cells (61). Recently it has been found that dysregulation of tRF-mediated translational regulatory circuitry impaired the stem cells growth, which was commonly associated with aggressive characteristics of human myelodysplastic syndromes (53).Ā In summary, TME were modified by tsRNAs, but the underlying molecular mechanisms of tsRNAs that regulated the TME remained yet not fully understood. Hence, our suggestion for future studies is that the focus should be on the elucidation of these mechanisms.
The Role of tsRNAs in the Modulation of Tumour Drug Resistance
Drug resistance is considered a vital factor determining the efficacy of anti-cancer therapies. Emerging evidence showed that some tsRNAs modulated the drug resistance of multiple tumours (24). For example, Cui etĀ al. found that the upregulated tDR-0009 and tDR-7336 sustained the interleukin-6 reactivity and finally participated in multidrug resistance by activating downstream pathways in triple-negative breast cancer cells (141). Meanwhile, another study showed that tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN orchestrated trastuzumab resistance in HER2-positiveĀ breast cancer cells (89). Sun etĀ al. studied the expression levels of tRFs in trastuzumab-sensitive and resistant breast cancer cell lines. The authors revealed the effect of tRFs on clinical trastuzumab efficacy using the Cox regression analysis. The obtained results highlight the need for further studies that aim at the accumulation of more data that will clarify the role of tRFs in the pathways that regulate the HER2-positiveĀ breast cancer drug resistance toward trastuzumab. In addition, other studies showcased that some downregulated tsRNAs were involved in the chemoresistance of lung cancer cells via integrin-linked kinase (ILK) signalling, phosphatase and tensin homolog (PTEN) signalling, and other pathways involved in the regulation of chemo-resistance (17, 142). Therefore, with the accumulating evidence on the role of tsRNA in tumour drug resistance, the clinical efficacy of anti-cancer drugs and the prognosis of cancer patients can progress to a new phase.
The Role of tsRNAs as Biomarkers for Cancer Diagnosis and Prognosis
Multiple ncRNAs have been regarded as potential biomarkers for cancer diagnosis and prognosis (143, 144). Recent studies have further proposed tsRNAs as novel tumour biomarkers (TableĀ 2). On one hand, some tsRNAs have demonstrated dysregulations in cancer tissues and serum samples. Hence, these tsRNAs were demonstrated as potential biomarkers for cancer diagnosis. For example, tRFs derived from tRNA-Met and tRNA-Val have been significantly elevated in the serum of pancreatic ductal adenocarcinoma (PDAC) patients as supposed by Xue and colleagues (82). Moreover, Li etĀ al. found that the expression of tRF-Pro-CGG was significantly downregulated in PDAC than this in normal pancreatic tissues, which was further associated with the TNM stage of patients. Thus, tRF-Pro-CGG has been considered as a biomarker for PDAC diagnosis and therapy (85). Similarly, tRFs derived from tRNALeu were significantly elevated in NSCLC tissues and serum samples, and therefore they were regarded as a potential biomarker for NSCLC diagnosis (100). In respect of tRFs in lung cancer, such as ts-46, ts-47, ts-3676 and ts-4521, they have been demonstrated as tumour suppressors based on recent reports as to the mechanism (17, 101). However, the clinical value of these tRFs needs to be clarified based on the registered clinical samples. Multiple investigations revealed that some tsRNAs derived from tRNA-Glu, tRNA-Gly, tRNA-Leu, and tRNA-Ser were significantly dysregulated in breast cancer serum samples (145). In another example of the Tripleānegative breast cancer, the expression of tDRā000620 was strongly correlated with age, node status and local recurrence as proposed by Feng etĀ al. In this study, the multivariate Cox regression demonstrated that the low expression of tDRā000620 was an adverse predictive factor for recurrenceāfree survival (87). Equally important were the findings of Huang etĀ al. who found that tRF-31-U5YKFN8DYDZDD was highly upregulated in serum samples of gastric cancer (GC) patients (146). All these results denoted that circulating tsRNAs could be a potential non-invasive indicator of a cancer diagnosis. On the other hand, these abnormally expressed tsRNAs were established as prognostic models for cancer treatments. For instance, tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN were demonstrated to shorten the progression-free survival (PFS) of trastuzumab-resistant breast carcinoma patients (89). Subsequently, data proved that these tRFs were likely to act as biomarkers for the prognosis of trastuzumab-resistant breast carcinoma patients (89). Additionally, another study demonstrated that tRFs derived from tRNA-Lys were associated with a higher risk for progression and poor clinical survival in bladder carcinoma (115). Thus, these data established a prognostic model for bladder cancer based on the expression levels of specific tsRNA. Recently, researchers have also discovered multiple tsRNA signatures in gastric cancer, papillary thyroid cancer, and other malignancies (38, 91, 93). The literature research on this matter highlighted the need for a broader validation of tsRNAs as sensitive biomarkers for cancer diagnosis and prognosis.
Summary and Perspectives
tsRNAs are a group of conventional small ncRNAs and play complicated roles in most malignancies. Their biological roles include regulation of cancer hallmarks, modification of TME, and modulation of drug resistance. Biofluid screening of miRNAs in clinical practice demonstrated that specific tsRNAs were upregulated in the biofluids of solid and blood malignancies (62, 147). Therefore, the biological functions of multiple tsRNAs in cancers have been widely studied. What is the most important from the aforementioned studies is that these functional tsRNAs potentially serve as novel biomarkers for cancer diagnosis and prognosis. However, for a deeper understanding of the tsRNA-related regulatory networks, further investigation is needed.
Our literature research showed that in the first place, the databases of tsRNAs, especially of tsRNAs in multiple tumours, should be perfected. Recently, biomedical investigations on tsRNAs in multiple cancers have been extensively driven by big data. Thus, OncotRF, tRFdb, and other tsRNA-related databases have been expansively applied in oncological research. However, there is no consensus among the existing databases in terms of the standardized terminology of tsRNAs (57, 148ā150). Consequently, the big data analytics for tsRNAs in multiple tumours is yet inefficient. Moreover, current studies have shown that tsRNAs are dysregulated in neoplasm tissues and serum samples of tumour patients. However, our knowledge concerning the upstream regulatory mechanism causing the abnormal expression of tsRNAs and the biological functions of tsRNAs in multiple tumours remains at a relatively superficial level. It is unknown whether the tsRNA dysregulation triggers the progress of tumours. Therefore, it is compulsory to identify the concrete molecular mechanisms of tsRNAs in regulating multiple tumours. Lately, enormous efforts were invested in the exploration of the mechanisms of tsRNAs in cancer cells. To advance clinical application of tsRNAs, future studies should focus on collecting patient samples with warranty of safety and efficacy, such as body fluids and tumour tissues. As it has already been reported, both tsRNAs and their precursor tRNAs contain various modifications (35, 36, 151). Interestingly, the modification status of tRNA can change the endonuclease activity and thus affect the tRNA cleavage process. However, the determination of exactly which tRNA modification affects tsRNA production in cancer progression as well as the potential relationship of tsRNA modification with their functions in tumours needs further investigation. Therefore, it is necessary to establish the localization and detection techniques for examining multiple RNA modifications of tsRNAs in various tumours. Based on detection techniques, the potential future research would focus on investigating upstream regulatory factors of tRNA modifications and endonuclease activity in tumours. Finally, diverse chemotherapies encounter drug resistance, which leads to the necessity of more targeted treatments. Moreover, the advent of RNA therapies bodes for the development of therapeutic approaches involving small RNAs. Thus, some tsRNAs, which are biologically correlated with tumour initiation and progression, are expected to become biomarkers for cancer diagnosis and prognosis. It is worth mentioning that tsRNAs can be encapsulated in exosomes and liquid biopsies based on exosomes can be a potential approach for molecular diagnosis in cancers. For example, some tRFs delivered via plasma exosomes served as a novel diagnostic biomarker in the liver cancer (102). These tRFs allow us to understand the pathological conditions of cancer patients by detecting specific tsRNAs encapsulated in exosomes. Moreover, engineered exosomes can load therapeutic miRNAs and anti-tumour drugs (152). Thus, therapeutic tsRNAs are likely to be another potential anti-tumour molecule loaded in engineered exosomes.
Given the abovementioned challenges, most tsRNA-related research on tumours has yet to be profound. Therefore, with the application of novel sequencing techniques and bioinformatics methods, such as photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) and cross-linking ligation and sequencing of hybrids (CLASH), more in-depth studies of tsRNAs in multiple tumours can provide a brand new insight into tumour cell biology for the establishment of solid foundations for further clinical applications of tsRNAs.
Funding
This study was supported by Jinhua central hospital basic research projects of Zhejiang China(Grant No: JY2021-6-05) and Zhejiang non-profit technology applied research projects of China (Grant No: LGF20H160017).
Publisherās Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
C-YX provided direction and guidance throughout the preparation of this manuscript. B-FF wrote and edited the manuscript. B-FF generated the figures and made significant revisions to the manuscript. All authors have read and approved the final version of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
WeiJWHuangKYangCKangCS. Non-Coding RNAs as Regulators in Epigenetics (Review). Oncol Rep (2017) 37:3ā9. doi: 10.3892/or.2016.5236
2
PennisiE. GenomicsENCODE Project Writes Eulogy for Junk DNA. Science (2012) 337:1159, 1161. doi: 10.1126/science.337.6099.1159
3
IsakovaANeffNQuakeSR. Single-Cell Quantification of a Broad RNA Spectrum Reveals Unique Noncoding Patterns Associated With Cell Types and States. Proc Natl Acad Sci USA (2021) 118. doi: 10.1073/pnas.2113568118
4
FuYLeeILeeYSBaoX. Small Non-Coding Transfer RNA-Derived RNA Fragments (tRFs): Their Biogenesis, Function and Implication in Human Diseases. Genomics Inform (2015) 13:94ā101. doi: 10.5808/GI.2015.13.4.94
5
StatelloLGuoCJChenLLHuarteM. Gene Regulation by Long non-Coding RNAs and its Biological Functions. Nat Rev Mol Cell Biol (2021) 22:96ā118. doi: 10.1038/s41580-020-00315-9
6
ZaratieguiMIrvineDVMartienssenRA. Noncoding RNAs and Gene Silencing. Cell (2007) 128:763ā76. doi: 10.1016/j.cell.2007.02.016
7
PontingCPOliverPLReikW. Evolution and Functions of Long Noncoding RNAs. Cell (2009) 136:629ā41. doi: 10.1016/j.cell.2009.02.006
8
HombachSKretzM. Non-Coding RNAs: Classification, Biology and Functioning. Adv Exp Med Biol (2016) 937:3ā17. doi: 10.1007/978-3-319-42059-2_1
9
HuntzingerEIzaurraldeE. Gene Silencing by microRNAs: Contributions of Translational Repression and mRNA Decay. Nat Rev Genet (2011) 12:99ā110. doi: 10.1038/nrg2936
10
Carvalho BarbosaCCalhounSHWiedenHJ. Non-Coding RNAs: What are We Missing? Biochem Cell Biol (2020) 98:23ā30. doi: 10.1139/bcb-2019-0037
11
MachadoIFTeodoroJSPalmeiraCMRoloAP. miR-378a: A New Emerging microRNA in Metabolism. Cell Mol Life Sci (2020) 77:1947ā58. doi: 10.1007/s00018-019-03375-z
12
FuXD. Non-Coding RNA: A New Frontier in Regulatory Biology. Natl Sci Rev (2014) 1:190ā204. doi: 10.1093/nsr/nwu008
13
BergMDBrandlCJ. Transfer RNAs: Diversity in Form and Function. RNA Biol (2021) 18:316ā39. doi: 10.1080/15476286.2020.1809197
14
WeiFYTomizawaK. tRNA Modifications and Islet Function. Diabetes Obes Metab (2018) 20 Suppl 2:20ā7. doi: 10.1111/dom.13405
15
YanasALiuKF. RNA Modifications and the Link to Human Disease. Methods Enzymol (2019) 626:133ā46. doi: 10.1016/bs.mie.2019.08.003
16
ZhangYDengQTuLLvDLiuD. Trnaderived Small RNAs: A Novel Class of Small RNAs in Human Hypertrophic Scar Fibroblasts. Int J Mol Med (2020) 45:115ā30. doi: 10.3892/ijmm.2019.4411
17
BalattiVNigitaGVenezianoDDruscoASteinGSMessierTLet al. tsRNA Signatures in Cancer. Proc Natl Acad Sci USA (2017) 114:8071ā6. doi: 10.1073/pnas.1706908114
18
LiSXuZShengJ. tRNA-Derived Small RNA: A Novel Regulatory Small Non-Coding RNA. Genes (Basel) (2018) 9:246. doi: 10.3390/genes9050246
19
ShenYYuXZhuLLiTYanZGuoJ. Transfer RNA-Derived Fragments and tRNA Halves: Biogenesis, Biological Functions and Their Roles in Diseases. J Mol Med (Berl) (2018) 96:1167ā76. doi: 10.1007/s00109-018-1693-y
20
ChoHLeeWKimGWLeeSHMoonJSKimMet al. Regulation of La/SSB-Dependent Viral Gene Expression by pre-tRNA 3ā Trailer-Derived tRNA Fragments. Nucleic Acids Res (2019) 47:9888ā901. doi: 10.1093/nar/gkz732
21
XiaoLWangJJuSCuiMJingR. Disorders and Roles of tsRNA, snoRNA, snRNA and piRNA in Cancer. J Med Genet (2022). doi: 10.1136/jmedgenet-2021-108327
22
KimHKFuchsGWangSWeiWZhangYParkHet al. A Transfer-RNA-Derived Small RNA Regulates Ribosome Biogenesis. Nature (2017) 552:57ā62. doi: 10.1038/nature25005
23
ParkJAhnSHShinMGKimHKChangS. tRNA-Derived Small RNAs: Novel Epigenetic Regulators. Cancers (Basel) (2020) 12:2773. doi: 10.3390/cancers12102773
24
ZhangYQianHHeJGaoW. Mechanisms of tRNA-Derived Fragments and tRNA Halves in Cancer Treatment Resistance. biomark Res (2020) 8:52. doi: 10.1186/s40364-020-00233-0
25
LuYZhengZYuanYPathakJLYangXWangLet al. The Emerging Role of Exosomes in Oral Squamous Cell Carcinoma. Front Cell Dev Biol (2021) 9:628103. doi: 10.3389/fcell.2021.628103
26
TaoEWWangHLChengWYLiuQQChenYXGaoQY. A Specific tRNA Half, 5ātirna-His-GTG, Responds to Hypoxia via the HIF1alpha/ANG Axis and Promotes Colorectal Cancer Progression by Regulating LATS2. J Exp Clin Cancer Res (2021) 40:67. doi: 10.1186/s13046-021-01836-7
27
JiaYTanWZhouY. Transfer RNA-Derived Small RNAs: Potential Applications as Novel Biomarkers for Disease Diagnosis and Prognosis. Ann Transl Med (2020) 8:1092. doi: 10.21037/atm-20-2797
28
KimHKYeomJHKayMA. Transfer RNA-Derived Small RNAs: Another Layer of Gene Regulation and Novel Targets for Disease Therapeutics. Mol Ther (2020) 28:2340ā57. doi: 10.1016/j.ymthe.2020.09.013
29
LiXLiuXZhaoDCuiWWuYZhangCet al. tRNA-Derived Small RNAs: Novel Regulators of Cancer Hallmarks and Targets of Clinical Application. Cell Death Discovery (2021) 7:249. doi: 10.1038/s41420-021-00647-1
30
TaxisTMBauermannFVRidpathJFCasasE. Analysis of tRNA Halves (tsRNAs) in Serum From Cattle Challenged With Bovine Viral Diarrhea Virus. Genet Mol Biol (2019) 42:374ā9. doi: 10.1590/1678-4685-gmb-2018-0019
31
DrinoAOberbauerVTrogerCJanisiwEAnratherDHartlMet al. Production and Purification of Endogenously Modified tRNA-Derived Small RNAs. RNA Biol (2020) 17:1104ā15. doi: 10.1080/15476286.2020.1733798
32
MaZZhouJShaoYJafariFAQiPLiY. Biochemical Properties and Progress in Cancers of tRNA-Derived Fragments. J Cell Biochem (2020) 121:2058ā63. doi: 10.1002/jcb.29492
33
QinCXuPPZhangXZhangCLiuCBYangDGet al. Pathological Significance of tRNA-Derived Small RNAs in Neurological Disorders. Neural Regener Res (2020) 15:212ā21. doi: 10.4103/1673-5374.265560
34
OberbauerVSchaeferMR. tRNA-Derived Small RNAs: Biogenesis, Modification, Function and Potential Impact on Human Disease Development. Genes (Basel) (2018) 9:607. doi: 10.3390/genes9120607
35
ChenQZhangXShiJYanMZhouT. Origins and Evolving Functionalities of tRNA-Derived Small RNAs. Trends Biochem Sci (2021) 46:790ā804. doi: 10.1016/j.tibs.2021.05.001
36
ZhangXCozenAELiuYChenQLoweTM. Small RNA Modifications: Integral to Function and Disease. Trends Mol Med (2016) 22:1025ā34. doi: 10.1016/j.molmed.2016.10.009
37
ZhouJWanFWangYLongJZhuX. Small RNA Sequencing Reveals a Novel tsRNA-26576 Mediating Tumorigenesis of Breast Cancer. Cancer Manag Res (2019) 11:3945ā56. doi: 10.2147/CMAR.S199281
38
ZhuYChenSLingZWinnickiAXuLXuSet al. Comprehensive Analysis of a tRNA-Derived Small RNA in Colorectal Cancer. Front Oncol (2021) 11:701440. doi: 10.3389/fonc.2021.701440
39
XieYYaoLYuXRuanYLiZGuoJ. Action Mechanisms and Research Methods of tRNA-Derived Small RNAs. Signal Transduct Target Ther (2020) 5:109. doi: 10.1038/s41392-020-00217-4
40
LeeYSShibataYMalhotraADuttaA. A Novel Class of Small RNAs: tRNA-Derived RNA Fragments (tRFs). Genes Dev (2009) 23:2639ā49. doi: 10.1101/gad.1837609
41
YuanYLiJHeZFanXMaoXYangMet al. tRNA-Derived Fragments as New Hallmarks of Aging and Age-Related Diseases. Aging Dis (2021) 12:1304ā22. doi: 10.14336/AD.2021.0115
42
YuXXieYZhangSSongXXiaoBYanZ. tRNA-Derived Fragments: Mechanisms Underlying Their Regulation of Gene Expression and Potential Applications as Therapeutic Targets in Cancers and Virus Infections. Theranostics (2021) 11:461ā9. doi: 10.7150/thno.51963
43
JiangPYanF. tiRNAs & tRFs Biogenesis and Regulation of Diseases: A Review. Curr Med Chem (2019) 26:5849ā61. doi: 10.2174/0929867326666190124123831
44
TaoEWChengWYLiWLYuJGaoQY. tiRNAs: A Novel Class of Small Noncoding RNAs That Helps Cells Respond to Stressors and Plays Roles in Cancer Progression. J Cell Physiol (2020) 235:683ā90. doi: 10.1002/jcp.29057
45
YamasakiSIvanovPHuGFAndersonP. Angiogenin Cleaves tRNA and Promotes Stress-Induced Translational Repression. J Cell Biol (2009) 185:35ā42. doi: 10.1083/jcb.200811106
46
SuZKuscuCMalikAShibataEDuttaA. Angiogenin Generates Specific Stress-Induced tRNA Halves and is Not Involved in tRF-3-Mediated Gene Silencing. J Biol Chem (2019) 294:16930ā41. doi: 10.1074/jbc.RA119.009272
47
HondaSLoherPShigematsuMPalazzoJPSuzukiRImotoIet al. Sex Hormone-Dependent tRNA Halves Enhance Cell Proliferation in Breast and Prostate Cancers. Proc Natl Acad Sci USA (2015) 112:E3816ā3825. doi: 10.1073/pnas.1510077112
48
HondaSKirinoY. SHOT-RNAs: A Novel Class of tRNA-Derived Functional RNAs Expressed in Hormone-Dependent Cancers. Mol Cell Oncol (2016) 3:e1079672. doi: 10.1080/23723556.2015.1079672
49
ZhangYZhangXShiJTuortoFLiXLiuYet al. Dnmt2 Mediates Intergenerational Transmission of Paternally Acquired Metabolic Disorders Through Sperm Small non-Coding RNAs. Nat Cell Biol (2018) 20:535ā40. doi: 10.1038/s41556-018-0087-2
50
OntiverosRJShenHStouteJYanasACuiYZhangYet al. Coordination of mRNA and tRNA Methylations by TRMT10A. Proc Natl Acad Sci USA (2020) 117:7782ā91. doi: 10.1073/pnas.1913448117
51
ZhangJLuRZhangYMatuszekZZhangWXiaYet al. tRNA Queuosine Modification Enzyme Modulates the Growth and Microbiome Recruitment to Breast Tumors. Cancers (Basel) (2020) 12:628. doi: 10.21203/rs.2.21087/v1
52
DimitrovaDGTeyssetLCarreC. RNA 2ā-O-Methylation (Nm) Modification in Human Diseases. Genes (Basel) (2019) 10:117. doi: 10.3390/genes10020117
53
GuzziNCieslaMNgocPCTLangSAroraSDimitriouMet al. Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells. Cell (2018) 173:1204ā16:e1226. doi: 10.1016/j.cell.2018.03.008
54
KawaradaLSuzukiTOhiraTHirataSMiyauchiKSuzukiT. ALKBH1 is an RNA Dioxygenase Responsible for Cytoplasmic and Mitochondrial tRNA Modifications. Nucleic Acids Res (2017) 45:7401ā15. doi: 10.1093/nar/gkx354
55
ZongTYangYZhaoHLiLLiuMFuXet al. tsRNAs: Novel Small Molecules From Cell Function and Regulatory Mechanism to Therapeutic Targets. Cell Prolif (2021) 54:e12977. doi: 10.1111/cpr.12977
56
KumarPMudunuriSBAnayaJDuttaA. Trfdb: A Database for Transfer RNA Fragments. Nucleic Acids Res (2015) 43:D141ā145. doi: 10.1093/nar/gku1138
57
YaoDSunXZhouLAmanullahMPanXLiuYet al. OncotRF: An Online Resource for Exploration of tRNA-Derived Fragments in Human Cancers. RNA Biol (2020) 17:1081ā91. doi: 10.1080/15476286.2020.1776506
58
KuscuCKumarPKiranMSuZMalikADuttaA. tRNA Fragments (tRFs) Guide Ago to Regulate Gene Expression Post-Transcriptionally in a Dicer-Independent Manner. RNA (2018) 24:1093ā105. doi: 10.1261/rna.066126.118
59
ZhouYPengHCuiQZhouY. Trftar: Prediction of tRF-Target Gene Interactions via Systemic Re-Analysis of Argonaute CLIP-Seq Datasets. Methods (2021) 187:57ā67. doi: 10.1016/j.ymeth.2020.10.006
60
MauteRLSchneiderCSumazinPHolmesACalifanoABassoKet al. tRNA-Derived microRNA Modulates Proliferation and the DNA Damage Response and is Down-Regulated in B Cell Lymphoma. Proc Natl Acad Sci USA (2013) 110:1404ā9. doi: 10.1073/pnas.1206761110
61
HuangBYangHChengXWangDFuSShenWet al. tRF/miR-1280 Suppresses Stem Cell-Like Cells and Metastasis in Colorectal Cancer. Cancer Res (2017) 77:3194ā206. doi: 10.1158/0008-5472.CAN-16-3146
62
LiZEnderCMeisterGMoorePSChangYJohnB. Extensive Terminal and Asymmetric Processing of Small RNAs From rRNAs, snoRNAs, snRNAs, and tRNAs. Nucleic Acids Res (2012) 40:6787ā99. doi: 10.1093/nar/gks307
63
HausseckerDHuangYLauAParameswaranPFireAZKayMA. Human tRNA-Derived Small RNAs in the Global Regulation of RNA Silencing. RNA (2010) 16:673ā95. doi: 10.1261/rna.2000810
64
ZhongFHuZJiangKLeiBWuZYuanGet al. Complement C3 Activation Regulates the Production of tRNA-Derived Fragments Gly-tRFs and Promotes Alcohol-Induced Liver Injury and Steatosis. Cell Res (2019) 29:548ā61. doi: 10.1038/s41422-019-0175-2
65
ChoiEJRenJZhangKWuWLeeYSLeeIet al. The Importance of AGO 1 and 4 in Post-Transcriptional Gene Regulatory Function of Trf5-GluCTC, an Respiratory Syncytial Virus-Induced tRNA-Derived RNA Fragment. Int J Mol Sci (2020) 21:8766. doi: 10.3390/ijms21228766
66
GreenJAAnsariMYBallHCHaqqiTM. tRNA-Derived Fragments (tRFs) Regulate Post-Transcriptional Gene Expression via AGO-Dependent Mechanism in IL-1beta Stimulated Chondrocytes. Osteoarthritis Cartilage (2020) 28:1102ā10. doi: 10.1016/j.joca.2020.04.014
67
GoodarziHLiuXNguyenHCZhangSFishLTavazoieSF. Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement. Cell (2015) 161:790ā802. doi: 10.1016/j.cell.2015.02.053
68
LyonsSMGudanisDCoyneSMGdaniecZIvanovP. Identification of Functional Tetramolecular RNA G-Quadruplexes Derived From Transfer RNAs. Nat Commun (2017) 8:1127. doi: 10.1038/s41467-017-01278-w
69
LyonsSMKharelPAkiyamaYOjhaSDaveDTsvetkovVet al. Eif4g has Intrinsic G-Quadruplex Binding Activity That is Required for tiRNA Function. Nucleic Acids Res (2020) 48:6223ā33. doi: 10.1093/nar/gkaa336
70
GebetsbergerJWyssLMleczkoAMReutherJPolacekN. A tRNA-Derived Fragment Competes With mRNA for Ribosome Binding and Regulates Translation During Stress. RNA Biol (2017) 14:1364ā73. doi: 10.1080/15476286.2016.1257470
71
CouvillionMTSachidanandamRCollinsK. A Growth-Essential Tetrahymena Piwi Protein Carries tRNA Fragment Cargo. Genes Dev (2010) 24:2742ā7. doi: 10.1101/gad.1996210
72
CouvillionMTBounovaGPurdomESpeedTPCollinsK. A Tetrahymena Piwi Bound to Mature tRNA 3ā Fragments Activates the Exonuclease Xrn2 for RNA Processing in the Nucleus. Mol Cell (2012) 48:509ā20. doi: 10.1016/j.molcel.2012.09.010
73
KimHKXuJChuKParkHJangHLiPet al. A tRNA-Derived Small RNA Regulates Ribosomal Protein S28 Protein Levels After Translation Initiation in Humans and Mice. Cell Rep (2019) 29:3816ā3824.e3814. doi: 10.1016/j.celrep.2019.11.062
74
WatanabeTTomizawaSMitsuyaKTotokiYYamamotoYKuramochi-MiyagawaSet al. Role for piRNAs and Noncoding RNA inDe Novo DNA Methylation of the Imprinted Mouse Rasgrf1 Locus. Science (2011) 332:848ā52. doi: 10.1126/science.1203919
75
SchornAJGutbrodMJLeblancCMartienssenR. LTR-Retrotransposon Control by tRNA-Derived Small RNAs. Cell (2017) 170:61ā71.e11. doi: 10.1016/j.cell.2017.06.013
76
PengHShiJZhangYZhangHLiaoSLiWet al. A Novel Class of tRNA-Derived Small RNAs Extremely Enriched in Mature Mouse Sperm. Cell Res (2012) 22:1609ā12. doi: 10.1038/cr.2012.141
77
ChenQYanMCaoZLiXZhangYShiJet al. Sperm tsRNAs Contribute to Intergenerational Inheritance of an Acquired Metabolic Disorder. Science (2016) 351:397ā400. doi: 10.1126/science.aad7977
78
SharmaUConineCCSheaJMBoskovicADerrAGBingXYet al. Biogenesis and Function of tRNA Fragments During Sperm Maturation and Fertilization in Mammals. Science (2016) 351:391ā6. doi: 10.1126/science.aad6780
79
ZhangYShiJChenQ. tsRNAs: New Players in Mammalian Retrotransposon Control. Cell Res (2017) 27:1307ā8. doi: 10.1038/cr.2017.109
80
SiomiMCSatoKPezicDAravinAA. PIWI-Interacting Small RNAs: The Vanguard of Genome Defence. Nat Rev Mol Cell Biol (2011) 12:246ā58. doi: 10.1038/nrm3089
81
ZhangXHeXLiuCLiuJHuQPanTet al. IL-4 Inhibits the Biogenesis of an Epigenetically Suppressive PIWI-Interacting RNA To Upregulate CD1a Molecules on Monocytes/Dendritic Cells. J Immunol (2016) 196:1591ā603. doi: 10.4049/jimmunol.1500805
82
XueMShiMXieJZhangJJiangLDengXet al. Serum tRNA-Derived Small RNAs as Potential Novel Diagnostic Biomarkers for Pancreatic Ductal Adenocarcinoma. Am J Cancer Res (2021) 11:837ā48. doi: 10.21203/rs.3.rs-63978/v1
83
FarinaNHScaliaSAdamsCEHongDFritzAJMessierTLet al. Identification of tRNA-Derived Small RNA (tsRNA) Responsive to the Tumor Suppressor, RUNX1, in Breast Cancer. J Cell Physiol (2020) 235:5318ā27. doi: 10.1002/jcp.29419
84
ZhuPLuJZhiXZhouYWangXWangCet al. tRNA-Derived Fragment Trflys-CTT-010 Promotes Triple-Negative Breast Cancer Progression by Regulating Glucose Metabolism via G6PC. Carcinogenesis (2021) 42:1196ā207. doi: 10.1093/carcin/bgab058
85
LiJJinLGaoYGaoPMaLZhuBet al. Low Expression of tRF-Pro-CGG Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma. J Clin Lab Anal (2021) 35:e23742. doi: 10.1002/jcla.23742
86
WangJMaGGeHHanXMaoXWangXet al. Circulating tRNA-Derived Small RNAs (tsRNAs) Signature for the Diagnosis and Prognosis of Breast Cancer. NPJ Breast Cancer (2021) 7:4. doi: 10.1038/s41523-020-00211-7
87
FengWLiYChuJLiJZhangYDingXet al. Identification of tRNA-Derived Small Noncoding RNAs as Potential Biomarkers for Prediction of Recurrence in Triple-Negative Breast Cancer. Cancer Med (2018) 7:5130ā44. doi: 10.1002/cam4.1761
88
FalconiMGiangrossiMZabaletaMEWangJGambiniVTilioMet al. A Novel 3ā-tRNA(Glu)-Derived Fragment Acts as a Tumor Suppressor in Breast Cancer by Targeting Nucleolin. FASEB J (2019) 33:13228ā40. doi: 10.1096/fj.201900382RR
89
SunCYangFZhangYChuJWangJWangYet al. tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer. Cell Physiol Biochem (2018) 49:419ā31. doi: 10.1159/000492977
90
ZhuLLiTShenYYuXXiaoBGuoJ. Using tRNA Halves as Novel Biomarkers for the Diagnosis of Gastric Cancer. Cancer biomark (2019) 25:169ā76. doi: 10.3233/CBM-182184
91
XuWZhouBWangJTangLHuQWangJet al. tRNA-Derived Fragment tRF-Glu-TTC-027 Regulates the Progression of Gastric Carcinoma via MAPK Signaling Pathway. Front Oncol (2021) 11:733763. doi: 10.3389/fonc.2021.733763
92
ShenYXieYYuXZhangSWenQYeGet al. Clinical Diagnostic Values of Transfer RNA-Derived Fragment tRF-19-3L7L73JD and its Effects on the Growth of Gastric Cancer Cells. J Cancer (2021) 12:3230ā8. doi: 10.7150/jca.51567
93
ShenYYuXRuanYLiZXieYYanZet al. Global Profile of tRNA-Derived Small RNAs in Gastric Cancer Patient Plasma and Identification of tRF-33-P4R8YP9LON4VDP as a New Tumor Suppressor. Int J Med Sci (2021) 18:1570ā9. doi: 10.7150/ijms.53220
94
DongXFanXHeXChenSHuangWGaoJet al. Comprehensively Identifying the Key tRNA-Derived Fragments and Investigating Their Function in Gastric Cancer Processes. Onco Targets Ther (2020) 13:10931ā43. doi: 10.2147/OTT.S266130
95
XiongWWangXCaiXXiongWLiuYLiCet al. Identification of Trnaderived Fragments in Colon Cancer by Comprehensive Small RNA Sequencing. Oncol Rep (2019) 42:735ā44. doi: 10.3892/or.2019.7178
96
LiSShiXChenMXuNSunDBaiRet al. Angiogenin Promotes Colorectal Cancer Metastasis via tiRNA Production. Int J Cancer (2019) 145:1395ā407. doi: 10.1002/ijc.32245
97
LuanNChenYLiQMuYZhouQYeXet al. TRF-20-M0NK5Y93 Suppresses the Metastasis of Colon Cancer Cells by Impairing the Epithelial-to-Mesenchymal Transition Through Targeting Claudin-1. Am J Transl Res (2021) 13:124ā42.
98
OlvedyMScaravilliMHoogstrateYVisakorpiTJensterGMartens-UzunovaES. A Comprehensive Repertoire of tRNA-Derived Fragments in Prostate Cancer. Oncotarget (2016) 7:24766ā77. doi: 10.18632/oncotarget.8293
99
YangCLeeMSongGLimW. tRNA(Lys)-Derived Fragment Alleviates Cisplatin-Induced Apoptosis in Prostate Cancer Cells. Pharmaceutics (2021) 13:55. doi: 10.3390/pharmaceutics13010055
100
ShaoYSunQLiuXWangPWuRMaZ. tRF-Leu-CAG Promotes Cell Proliferation and Cell Cycle in non-Small Cell Lung Cancer. Chem Biol Drug Des (2017) 90:730ā8. doi: 10.1111/cbdd.12994
101
PekarskyYBalattiVPalamarchukARizzottoLVenezianoDNigitaGet al. Dysregulation of a Family of Short Noncoding RNAs, tsRNAs, in Human Cancer. Proc Natl Acad Sci USA (2016) 113:5071ā6. doi: 10.1073/pnas.1604266113
102
ZhuLLiJGongYWuQTanSSunDet al. Exosomal tRNA-Derived Small RNA as a Promising Biomarker for Cancer Diagnosis. Mol Cancer (2019) 18:74. doi: 10.1186/s12943-019-1000-8
103
ZhouYHuJLiuLYanMZhangQSongXet al. Gly-tRF Enhances LCSC-Like Properties and Promotes HCC Cells Migration by Targeting NDFIP2. Cancer Cell Int (2021) 21:502. doi: 10.1186/s12935-021-02102-8
104
ZhangMLiFWangJHeWLiYLiHet al. tRNA-Derived Fragment tRF-03357 Promotes Cell Proliferation, Migration and Invasion in High-Grade Serous Ovarian Cancer. Onco Targets Ther (2019) 12:6371ā83. doi: 10.2147/OTT.S206861
105
PengEYShuYWuYZengFTanSDengYet al. Presence and Diagnostic Value of Circulating tsncRNA for Ovarian Tumor. Mol Cancer (2018) 17:163. doi: 10.1186/s12943-018-0910-1
106
WangBGYanLRXuQZhongXP. The Role of Transfer RNA-Derived Small RNAs (tsRNAs) in Digestive System Tumors. J Cancer (2020) 11:7237ā45. doi: 10.7150/jca.46055
107
KarousiPAdamopoulosPGPapageorgiouSGPappaVScorilasAKontosCK. A Novel, Mitochondrial, Internal tRNA-Derived RNA Fragment Possesses Clinical Utility as a Molecular Prognostic Biomarker in Chronic Lymphocytic Leukemia. Clin Biochem (2020) 85:20ā6. doi: 10.1016/j.clinbiochem.2020.07.005
108
KarousiPKatsarakiKPapageorgiouSGPappaVScorilasAKontosCK. Identification of a Novel tRNA-Derived RNA Fragment Exhibiting High Prognostic Potential in Chronic Lymphocytic Leukemia. Hematol Oncol (2019) 37:498ā504. doi: 10.1002/hon.2616
109
KatsarakiKArtemakiPIPapageorgiouSGPappaVScorilasAKontosCK. Identification of a Novel, Internal tRNA-Derived RNA Fragment as a New Prognostic and Screening Biomarker in Chronic Lymphocytic Leukemia, Using an Innovative Quantitative Real-Time PCR Assay. Leuk Res (2019) 87:106234. doi: 10.1016/j.leukres.2019.106234
110
FabrisLJuracekJCalinG. Non-Coding RNAs as Cancer Hallmarks in Chronic Lymphocytic Leukemia. Int J Mol Sci (2020) 21:6720. doi: 10.3390/ijms21186720
111
KatsarakiKAdamopoulosPGPapageorgiouSGPappaVScorilasAKontosCK. A 3ā tRNA-Derived Fragment Produced by tRNA(LeuAAG) and tRNA(LeuTAG) is Associated With Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia, Independently of Classical Prognostic Factors. Eur J Haematol (2021) 106:821ā30. doi: 10.1111/ejh.13613
112
NientiedtMDengMSchmidtDPernerSMullerSCEllingerJ. Identification of Aberrant tRNA-Halves Expression Patterns in Clear Cell Renal Cell Carcinoma. Sci Rep (2016) 6:37158. doi: 10.1038/srep37158
113
ZhaoCTolkachYSchmidtDKristiansenGMullerSCEllingerJ. 5ā-tRNA Halves are Dysregulated in Clear Cell Renal Cell Carcinoma. J Urol (2018) 199:378ā83. doi: 10.1016/j.juro.2017.07.082
114
IvanovPEmaraMMVillenJGygiSPAndersonP. Angiogenin-Induced tRNA Fragments Inhibit Translation Initiation. Mol Cell (2011) 43:613ā23. doi: 10.1016/j.molcel.2011.06.022
115
PapadimitriouMAAvgerisMLevisPPapasotiriouECKotronopoulosGStravodimosKet al. tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5ā-tRF-LysCTT Results in Disease Early Progression and Patientsā Poor Treatment Outcome. Cancers (Basel) (2020) 12:3661. doi: 10.3390/cancers12123661
116
ShanSWangYZhuC. A Comprehensive Expression Profile of tRNA-Derived Fragments in Papillary Thyroid Cancer. J Clin Lab Anal (2021) 35:e23664. doi: 10.1002/jcla.23664
117
GuXWangLCoatesPJBoldrupLFahraeusRWilmsTet al. Transfer-RNA-Derived Fragments Are Potential Prognostic Factors in Patients With Squamous Cell Carcinoma of the Head and Neck. Genes (Basel) (2020) 11:1344. doi: 10.3390/genes11111344
118
MoDJiangPYangYMaoXTanXTangXet al. A tRNA Fragment, 5ā-tiRNA(Val), Suppresses the Wnt/beta-Catenin Signaling Pathway by Targeting FZD3 in Breast Cancer. Cancer Lett (2019) 457:60ā73. doi: 10.1016/j.canlet.2019.05.007
119
HuangYGeHZhengMCuiYFuZWuXet al. Serum tRNA-Derived Fragments (tRFs) as Potential Candidates for Diagnosis of Nontriple Negative Breast Cancer. J Cell Physiol (2020) 235:2809ā24. doi: 10.1002/jcp.29185
120
RoungeTBFuruKSkotheimRIHaugenTBGrotmolTEnerlyE. Profiling of the Small RNA Populations in Human Testicular Germ Cell Tumors Shows Global Loss of piRNAs. Mol Cancer (2015) 14:153. doi: 10.1186/s12943-015-0411-4
121
ZhouKDiebelKWHolyJSkildumAOdeanEHicksDAet al. A tRNA Fragment, Trf5-Glu, Regulates BCAR3 Expression and Proliferation in Ovarian Cancer Cells. Oncotarget (2017) 8:95377ā91. doi: 10.18632/oncotarget.20709
122
MaZLZhangBJWangDTLiXWeiJLZhaoBTet al. Tanshinones Suppress AURKA Through Up-Regulation of miR-32 Expression in non-Small Cell Lung Cancer. Oncotarget (2015) 6:20111ā20. doi: 10.18632/oncotarget.3933
123
HuFNiuYMaoXCuiJWuXSimoneCB2ndet al. tsRNA-5001a Promotes Proliferation of Lung Adenocarcinoma Cells and is Associated With Postoperative Recurrence in Lung Adenocarcinoma Patients. Transl Lung Cancer Res (2021) 10:3957ā72. doi: 10.21037/tlcr-21-829
124
TamuraREDe VasconcellosJFSarkarDLibermannTAFisherPBZerbiniLF. GADD45 Proteins: Central Players in Tumorigenesis. Curr Mol Med (2012) 12:634ā51. doi: 10.2174/156652412800619978
125
HaringSJMasonACBinzSKWoldMS. Cellular Functions of Human RPA1. Multiple Roles of Domains in Replication, Repair, and Checkpoints. J Biol Chem (2008) 283:19095ā111. doi: 10.1074/jbc.M800881200
126
HanahanDWeinbergRA. Hallmarks of Cancer: The Next Generation. Cell (2011) 144:646ā74. doi: 10.1016/j.cell.2011.02.013
127
ElbarbaryRATakakuHUchiumiNTamiyaHAbeMTakahashiMet al. Modulation of Gene Expression by Human Cytosolic Trnase Z(L) Through 5ā-half-tRNA. PloS One (2009) 4:e5908. doi: 10.1371/journal.pone.0005908
128
FaresJFaresMYKhachfeHHSalhabHAFaresY. Molecular Principles of Metastasis: A Hallmark of Cancer Revisited. Signal Transduct Target Ther (2020) 5:28. doi: 10.1038/s41392-020-0134-x
129
LondinEMageeRShieldsCLLallySESatoTRigoutsosI. IsomiRs and tRNA-Derived Fragments are Associated With Metastasis and Patient Survival in Uveal Melanoma. Pigment Cell Melanoma Res (2020) 33:52ā62. doi: 10.1111/pcmr.12810
130
BirchJClarkeCJCampbellADCampbellKMitchellLLikoDet al. The Initiator Methionine tRNA Drives Cell Migration and Invasion Leading to Increased Metastatic Potential in Melanoma. Biol Open (2016) 5:1371ā9. doi: 10.1242/bio.019075
131
PeinadoHZhangHMateiIRCosta-SilvaBHoshinoARodriguesGet al. Pre-Metastatic Niches: Organ-Specific Homes for Metastases. Nat Rev Cancer (2017) 17:302ā17. doi: 10.1038/nrc.2017.6
132
PastushenkoIBlanpainC. EMT Transition States During Tumor Progression and Metastasis. Trends Cell Biol (2019) 29:212ā26. doi: 10.1016/j.tcb.2018.12.001
133
ZhangFShiJWuZGaoPZhangWQuBet al. A 3ā-tRNA-Derived Fragment Enhances Cell Proliferation, Migration and Invasion in Gastric Cancer by Targeting FBXO47. Arch Biochem Biophys (2020) 690:108467. doi: 10.1016/j.abb.2020.108467
134
MoDHeFZhengJChenHTangLYanF. tRNA-Derived Fragment tRF-17-79mp9pp Attenuates Cell Invasion and Migration via THBS1/TGF-Beta1/Smad3 Axis in Breast Cancer. Front Oncol (2021) 11:656078. doi: 10.3389/fonc.2021.656078
135
HinshawDCShevdeLA. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res (2019) 79:4557ā66. doi: 10.1158/0008-5472.CAN-18-3962
136
SlackFJChinnaiyanAM. The Role of Non-Coding RNAs in Oncology. Cell (2019) 179:1033ā55. doi: 10.1016/j.cell.2019.10.017
137
ChenQLiYLiuYXuWZhuX. Exosomal Non-Coding RNAs-Mediated Crosstalk in the Tumor Microenvironment. Front Cell Dev Biol (2021) 9:646864. doi: 10.3389/fcell.2021.646864
138
ClaraJAMongeCYangYTakebeN. Targeting Signalling Pathways and the Immune Microenvironment of Cancer Stem Cells - a Clinical Update. Nat Rev Clin Oncol (2020) 17:204ā32. doi: 10.1038/s41571-019-0293-2
139
SistiguAMusellaMGalassiCVitaleIDe MariaR. Tuning Cancer Fate: Tumor Microenvironmentās Role in Cancer Stem Cell Quiescence and Reawakening. Front Immunol (2020) 11:2166. doi: 10.3389/fimmu.2020.02166
140
GuzziNBellodiC. Novel Insights Into the Emerging Roles of tRNA-Derived Fragments in Mammalian Development. RNA Biol (2020) 17:1214ā22. doi: 10.1080/15476286.2020.1732694
141
CuiYHuangYWuXZhengMXiaYFuZet al. Hypoxia-Induced tRNA-Derived Fragments, Novel Regulatory Factor for Doxorubicin Resistance in Triple-Negative Breast Cancer. J Cell Physiol (2019) 234:8740ā51. doi: 10.1002/jcp.27533
142
JiaZ. Role of Integrin-Linked Kinase in Drug Resistance of Lung Cancer. Onco Targets Ther (2015) 8:1561ā5. doi: 10.2147/OTT.S81447
143
SawPEXuXChenJSongEW. Non-Coding RNAs: The New Central Dogma of Cancer Biology. Sci China Life Sci (2021) 64:22ā50. doi: 10.1007/s11427-020-1700-9
144
WeiGZhuJHuHBLiuJQ. Circular RNAs: Promising Biomarkers for Cancer Diagnosis and Prognosis. Gene (2021) 771:145365. doi: 10.1016/j.gene.2020.145365
145
WangJMaGLiMHanXXuJLiangMet al. Plasma tRNA Fragments Derived From 5ā Ends as Novel Diagnostic Biomarkers for Early-Stage Breast Cancer. Mol Ther Nucleic Acids (2020) 21:954ā64. doi: 10.1016/j.omtn.2020.07.026
146
HuangYZhangHGuXQinSZhengMShiXet al. Elucidating the Role of Serum tRF-31-U5YKFN8DYDZDD as a Novel Diagnostic Biomarker in Gastric Cancer (Gc). Front Oncol (2021) 11:723753. doi: 10.3389/fonc.2021.723753
147
ZhangSSunLKraglerF. The Phloem-Delivered RNA Pool Contains Small Noncoding RNAs and Interferes With Translation. Plant Physiol (2009) 150:378ā87. doi: 10.1104/pp.108.134767
148
XuWLYangYWangYDQuLHZhengLL. Computational Approaches to tRNA-Derived Small RNAs. Noncoding RNA (2017) 3:2. doi: 10.3390/ncrna3010002
149
SaleembhashaAMishraS. Novel Molecules lncRNAs, tRFs and circRNAs Deciphered From Next-Generation Sequencing/RNA Sequencing: Computational Databases and Tools. Brief Funct Genomics (2018) 17:15ā25. doi: 10.1093/bfgp/elx013
150
LiNShanNLuLWangZ. Trftarget: A Database for Transfer RNA-Derived Fragment Targets. Nucleic Acids Res (2021) 49:D254ā60. doi: 10.1093/nar/gkaa831
151
ZhangXTrebakFSouzaLACShiJZhouTKehoePGet al. Small RNA Modifications in Alzheimerās Disease. Neurobiol Dis (2020) 145:105058. doi: 10.1016/j.nbd.2020.105058
152
LiangGZhuYAliDJTianTXuHSiKet al. Engineered Exosomes for Targeted Co-Delivery of miR-21 Inhibitor and Chemotherapeutics to Reverse Drug Resistance in Colon Cancer. J Nanobiotechnol (2020) 18:10. doi: 10.1186/s12951-019-0563-2
Summary
Keywords
tsRNAs, human carcinoma, biomarker, carcinogenesis, diagnosis
Citation
Fu B-F and Xu C-Y (2022) Transfer RNA-Derived Small RNAs: Novel Regulators and Biomarkers of Cancers. Front. Oncol. 12:843598. doi: 10.3389/fonc.2022.843598
Received
26 December 2021
Accepted
06 April 2022
Published
28 April 2022
Volume
12 - 2022
Edited by
Jian-ye Zhang, Guangzhou Medical University, China
Reviewed by
Christos K. Kontos, National and Kapodistrian University of Athens, Greece
Updates
Copyright
Ā© 2022 Fu and Xu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chao-Yang Xu, xuchaoyang@zju.edu.cn
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.